AJP - Heart Calcium Transients and Cell-Sarcomere
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Heart Circ Physiol 290: H985-H994, 2006. First published September 30, 2005; doi:10.1152/ajpheart.00720.2005
0363-6135/06 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
290/3/H985    most recent
00720.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (10)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ha, T.
Right arrow Articles by Li, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ha, T.
Right arrow Articles by Li, C.

Blockade of MyD88 attenuates cardiac hypertrophy and decreases cardiac myocyte apoptosis in pressure overload-induced cardiac hypertrophy in vivo

Tuanzhu Ha,1 Fang Hua,1 Yuehua Li,1 Jing Ma,1 Xiang Gao,2 Jim Kelley,3 Aiqiu Zhao,4 Georges E. Haddad,4 David L. Williams,1 I. William Browder,1 Race L. Kao,1 and Chuanfu Li1

Departments of 1Surgery and 3Internal Medicine, East Tennessee State University, Johnson City, Tennessee; 2Animal Model Research Center, Nanjing University, Nanjing, China; and Department of 4Physiology and Biophysics, Howard University, Washington DC

Submitted 6 July 2005 ; accepted in final form 23 September 2005


   ABSTRACT
TOP
 ABSTRACT
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
In this study, we evaluated whether blocking myeloid differentiation factor-88 (MyD88) could decrease cardiac myocyte apoptosis following pressure overload. Adenovirus expressing dominant negative MyD88 (Ad5-dnMyD88) or Ad5-green fluorescent protein (GFP) (Ad5-GFP) was transfected into rat hearts (n = 8/group) immediately followed by aortic banding for 3 wk. One group of rats (n = 8) was subjected to aortic banding for 3 wk without transfection. Sham surgical operation (n = 8) served as control. The ratios of heart weight to body weight (HW/BW) and heart weight to tibia length (HW/TL) were calculated. Cardiomyocyte size was examined by FITC-labeled wheat germ agglutinin staining of membranes. Cardiac myocyte apoptosis was determined by terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling assay, and myocardial interstitial fibrosis was examined by Masson's Trichrome staining. Aortic banding significantly increased the HW/BW by 41.0% (0.44 ± 0.013 vs. 0.31 ± 0.008), HW/TL by 47.2% (42.7 ± 1.30 vs. 29.0 ± 0.69), cardiac myocyte size by 49.6%, and cardiac myocyte apoptosis by 11.5%, and myocardial fibrosis and decreased cardiac function compared with sham controls. Transfection of Ad5-dnMyD88 significantly reduced the HW/BW by 18.2% (0.36 ± 0.006 vs. 0.44 ± 0.013) and HW/TL by 22.3% (33.2 ± 0.95 vs. 42.7 ± 1.30) and decreased cardiomyocyte size by 56.8%, cardiac myocyte apoptosis by 76.2%, as well as fibrosis, and improved cardiac function compared with aortic-banded group. Our results suggest that MyD88 is an important component in the Toll-like receptor-4-mediated nuclear factor-{kappa}B activation pathway that contributes to the development of cardiac hypertrophy. Blockade of MyD88 significantly reduced cardiac hypertrophy, cardiac myocyte apoptosis, and improved cardiac function in vivo.

dominant negative myeloid differentiation factor-88; nuclear factor-{kappa}B; signal transduction

IN VITRO STUDIES show that nuclear factor-{kappa}B (NF-{kappa}B) activation is involved in the hypertrophic response of cultured cardiomyocytes (4, 8, 12, 14, 27, 32). Inhibition of NF-{kappa}B activation significantly attenuates hypertrophic response in cultured cardiomyocytes (8, 27). We have demonstrated that NF-{kappa}B activation is required for the development of cardiac hypertrophy in vivo (21). NF-{kappa}B activation has been shown to play a critical role in regulating expression of groups of genes involved in immune and inflammatory responses, cell death and survival, cell growth, and cell cycle (2). NF-{kappa}B is a critical transcription factor in Toll-like receptor(s) (TLRs)-mediated signaling pathways (1, 23, 34). The main pathway of TLR-mediated signaling that leads to NF-{kappa}B activation involves the adaptor molecule termed myeloid differentiation factor-88 (MyD88), kinases of the IL-1 receptor-associated kinase (IRAK) family, TNF-receptor-associated factor 6 (TRAF6), NF-{kappa}B-inducing kinase (NIK), transforming growth factor (TGF)-beta-activated kinase 1 (TAK1), and I{kappa}B kinase (IKK) complexes (1, 34). MyD88 has been demonstrated to play an important role in the TLR-interleukin (IL)-receptor (TIR)-mediated NF-{kappa}B activation pathway (23). We have recently observed that TLR4 is an important receptor contributing to cardiac hypertrophy in vivo (13). MyD88 is a key adaptor protein for TLR signaling. Blockade of MyD88-mediated signaling attenuated the development of cardiac hypertrophy in vivo (22). It has been shown that cardiac myocyte apoptosis plays an important role in the transition of hypertrophic heart to heart failure (9, 25, 29). In the present study we examined whether blocking MyD88 could prevent cardiac myocyte death and improve cardiac function following aortic banding in vivo. We have observed that transfection of dominant negative MyD88 into the myocardium significantly reduced cardiac myocyte apoptosis and improved cardiac function in pressure overload-induced cardiac hypertrophy in rats. The results suggest that the MyD88-dependent signaling pathway plays a role in the cardiac myocyte death in pressure overload-induced cardiac hypertrophy in vivo.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Aortic banding induced cardiac hypertrophy in rats. Male Sprague-Dawley rats (225–250 g) were maintained in the Division of Laboratory Animal Resources at East Tennessee State University (ETSU) in accordance with the guidelines for the "Principles of Laboratory Animal Care" and the National Institutes of Health Guide for the Care and Use of Laboratory Animals. All aspects of the animal care and experimental protocols were approved by the ETSU Committee on Animal Care. Cardiac hypertrophy in rats was induced as previously described (21). Briefly, rats were anesthetized with isoflurane inhalation and ventilated with room air with the use of a rodent ventilator. The hearts were exposed through a left thoracotomy in the fourth intercostal space, and a suture (2-0 silk) was drawn under the ascending aorta. An 18-gauge needle was placed alongside the ascending aorta, and the suture was tightly tied together with the needle. The needle was then removed and the thorax was closed. The pressure gradient of aortic coarctation was 63 ± 2.5 mmHg after aortic banding. For the sham control, the identical procedure was performed, except without the tying of the suture around the aorta. Three weeks after the operation, the heart weight-to-body weight (HW/BW) ratio was calculated.

Construction of adenovirus expressing dominant negative MyD88. The dominant negative MyD88 (dnMyD88) cDNA was kindly provided by Dr. Jurg Tschopp at the Institute of Biochemistry, University Lausanne, Switzerland (6, 15). This dnMyD88 construct has been shown to significantly inhibit IL-1-induced NF-{kappa}B activation (6). To construct adenovirus expressing dnMyD88 (Ad5-dnMyD88), PCR was performed to amplify the dnMyD88 fragments containing FLAG (an eight amino acid sequence tag, Sigma) from the pCR3.V64-Met-Flag-Stop vector. The amplified DNA fragments were inserted into pShuttle vector at Xhol and KpnI sites followed by recombinant with double-deleted adenovirus type 5 (Ad5) vector. The double-deleted adenovirus expressing dnMyD88 (Ad5-dnMyD88) was packaged in 293A cells and purified by ultracentrifugation (21). The plaque forming units per milliter (pfu/ml) of Ad5-dnMyD88 were determined by tissue culture infectious dose 50 (TCID50) method according to the manufacturer's protocols (Quantum Biotechnologies, Montreal, Canada).

Expression of Ad5-dnMyD88 in H9C2 cardiomyoblasts. H9C2 rat cardiomyoblast cell line was obtained from the American Type Culture Collection (Rockville, MD) and was maintained in Dulbecco's modified Eagle's medium (DMEM)-supplemented 10% fetal bovine serum (FBS) under 5% CO2 at 37°C. When the cells reached 70–80% confluence, Ad5-dnMyD88 or Ad5-GFP (1 x 107 pfu/ml, pfu) was added into the cells. Twenty-four hours after transfection, the cells were stimulated with lipopolysaccharide (LPS) at 0.5 µg/ml for 30 min. The cells were harvested for analysis of NF-{kappa}B binding activity by EMSA (17–20) and for the expression of the transfected dnMyD88 and FLAG by Western blot analysis.

Adenovirus-mediated gene transfection into the myocardium in vivo. Transfection of Ad5-dnMyD88 (1 x 1010 pfu/ml) into the myocardium was performed as previously described (21). Ad5-GFP (1 x 1010 pfu/ml) served as the control. The transfection efficiency was examined by evaluation of green fluorescence protein (GFP) expression in the hearts (n = 3) 3 days after transfection of Ad5-GFP (21). The expressions of transfected dnMyD88 and FLAG were examined by Western blot analysis with specific anti-MyD88 and FLAG antibodies in the hearts (n = 2) at 3 days and 1, 2, and 3 wk after transfection of Ad5-dnMyD88. To determine the effect of transfected dnMyD88 on cardiac hypertrophy, Ad5-dnMyD88 (1 x 1010 pfu/ml) was transfected into the myocardium (n = 8) immediately followed by banding the aorta. Transfection of Ad5-GFP served as a control (n = 8). Two rats from each group were subjected to measurement of the pressure gradients 3 days after aortic banding, and the pressure gradients were 59 and 63 mmHg in the aortic banding group, 60 and 64 mmHg in the GFP group, and 66 and 59 mmHg in the dnMyD88 group. Three weeks after aortic banding was completed, the hearts were harvested, and the HW/BW was calculated. We chose the 3-wk time point because we have previously shown that transfection of adenovirus expressing I{kappa}B{alpha} mutant into the myocardium had a significant effect on the attenuation of cardiac hypertrophy (21).

Electrophoretic mobility shift assay. NF-{kappa}B activity was examined by electrophoretic mobility shift assay (EMSA) as previously described (17–20) in a 15-µl binding reaction mixture containing 15 µg of nuclear proteins and 35 fmols of {gamma}-32P-labeled double-stranded NF-{kappa}B consensus oligonucleotide. A supershift assay using antibodies to P65 and P50 was performed to confirm NF-{kappa}B binding specificity as previously described (17–20).

Western blot analysis. Western blot analysis was performed as previously described (17–20) with primary anti-FLAG and anti-MyD88 (Sigma), respectively, followed by peroxidase-conjugated second antibodies (Cell Signaling Technology). The membranes were analyzed by the ECL system (Amersham Pharmacia). The same membranes were probed with anti-GAPDH (Biodesign, Saco, ME) after being washed with stripping buffer. The signals were quantified by scanning densitometry and computer-assisted image analysis.

Histology. To evaluate the expression of GFP, the hearts were harvested, sectioned, and immersion-fixed in 4% buffered paraformaldehyde 3 days after transfection of Ad5-GFP. The tissues were cut at 5 µm, counterstained with hematoxylin and eosin, and examined by fluorescence microscopy (21). To examine histological change in aortic banding-induced cardiac hypertrophy, hearts were harvested 3 wk after aortic banding with or without Ad5-dnMyD88 transfection (n = 4 hearts/group) and prepared in the standard manner as previously described (21). Myocardial interstitial fibrosis was stained by Masson's Trichrome. The cardiac myocyte size was examined by FITC-labeled wheat germ agglutinin (Sigma) staining of membranes, and left ventricular cardiac myocyte membranes were observed by fluorescence microscopy. Morphometric analysis was performed with a phospho-Imager system (Bio-Rad). A value from each heart was calculated by use of the measurements of 40–50 cells from an individual heart. The results were expressed as mean values ± SE from each experimental group.

In situ apoptosis assay. In situ cell death examination was performed as previously described (18). Hearts harvested from each group (n = 4/group) were sectioned and embedded in paraffin. Three slides from each block were evaluated for percentage of apoptotic cells by using the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay (Boehringer Mannheim, Indianapolis, IN). Four slide fields were randomly examined by using a defined rectangular field area with magnification x200. Fifty cells were counted in each field.

Immunohistochemistry. Caspase-3 activity was assessed in the heart sections by immunohistochemistry using specific anti-capase-3 cleaved antibody (Cell Signaling Technology) (31). Briefly, hearts from each group (n = 4) were harvested and immersion fixed in 4% buffered paraformaldehyde, embedded in paraffin, cut at 5 µm, and stained with an antibody directed against activated caspase-3 (31). Three slides from each block were evaluated with brightfield microscopy.

Hemodynamic measurements. Rats were anesthetized with isoflurane inhalation and ventilated with room air with the use of a rodent ventilator. A microconductance pressure catheter (Millar Instruments, Houston, TX) was positioned in the left ventricle (LV) via the right carotid artery for continuous registration of LV pressure-volume loops (16) by using the PowerLab system (AD Instruments, Colorado Springs, CO). A cuvette calibration method was used to convert the conductance voltage into volume units by filling nonconductive cuvettes of known diameter with heparin-treated rat blood. Parallel conductance from surrounding structures was determined by intravenous (external jugular vein) injection of a small bolus (15 µl) of hypertonic saline (15% NaCl). All measurements were performed while ventilation was turned off momentarily. Indexes of systolic and diastolic cardiac performance were derived from LV pressure-volume data obtained at steady state. Cardiac output, ejection fraction, stroke volume, and stroke work were chosen as indexes for cardiac function change.

Statistical analysis. Results are expressed as means ± SE. For tests of significance between the groups, one-way analysis of variance (ANOVA) and Tukey's procedure for multiple range tests were performed. P < 0.05 was considered to be significant.


   RESULTS
TOP
 ABSTRACT
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
Expression of dnMyD88 in H9C2 cardiomyoblasts. The expression of Ad5-dnMyD88 in the rat cardiac myoblasts cell line H9C2 (n = 3) was examined 24 h after transfection with Ad5-dnMyD88 (1 x 107 pfu/ml). Ad5-GFP served as a control (n = 3). Because Ad5-dnMyD88 contains a FLAG epitope, we also examined the expression of FLAG with a specific antibody. As shown in Fig. 1, dnMyD88 and FLAG migrated with a molecular mass of 17 kDa in SDS-PAGE (6) and were detected in the cells transfected with Ad5-dnMyD88 but not detected in untransfected cells or in cells transfected with Ad5-GFP.


Figure 1
View larger version (37K):
[in this window]
[in a new window]
  		Fig. 1. Expression of adenovirus expressing dominant negative myeloid differentiation factor-88 (MyD88) (dnMyD88) in cultured rat cardiomyoblasts H9C2 cell line. Ad5-dnMyD88 or Ad5-green fluorescent protein (GFP) (1 x 107 pfu/ml) was transfected into H9C2 rat cardiomyoblasts. Twenty-four hours after transfection, the cells were harvested and cytoplasmic proteins were isolated for Western blot analysis of the expression of FLAG and dnMyD88 with specific antibodies. The expressed FLAG or dnMyD88 is labeled on the right. FLAG, a fusion protein tag.

 
Transfection of dnMyD88 inhibits LPS-induced NF-{kappa}B activation in H9C2 cardiomyoblasts. To examine the effect of Ad5-dnMyD88 on NF-{kappa}B activation, rat cardiomyoblasts were transfected with Ad5-dnMyD88 (n = 3) (1 x 107 pfu/ml), and Ad5-GFP served as a control (n = 3). Twenty-four hours after transfection, the cells were stimulated with LPS (0.5 µg/ml) for 30 min before NF-{kappa}B binding activity was examined by EMSA as previously described (17–20). As shown in Fig. 2, transfection of Ad5-dnMyD88 into H9C2 cells significantly inhibited NF-{kappa}B activation stimulated by LPS. Transfection of Ad5-GFP did not affect LPS-induced NF-{kappa}B activation.


Figure 2
View larger version (61K):
[in this window]
[in a new window]
  		Fig. 2. Ad5-dnMyD88 inhibits NF-{kappa}B activation in cultured H9C2 cardiomyoblasts stimulated by LPS. Ad5-dnMyD88 or Ad5-GFP (1 x 107 pfu/ml) was transfected into rat H9C2 cardiomyoblasts. Twenty-four hours after transfection, the cells were stimulated with LPS (0.5 µg/ml) for 30 min. The nuclear proteins were isolated for electrophoretic mobility shift assay (EMSA) analysis of NF-{kappa}B binding activity. The NF-{kappa}B binding band is labeled on the right.

 
Expression of dnMyD88 in the myocardium. The transfection efficiency and the expression of Ad5-dnMyD88 in the myocardium were evaluated in the hearts 3 days after transfection with Ad5-GFP or Ad5-dnMyD88 at 1 x 1010 pfu/ml. GFP expression was examined by fluorescence microscopy, and dnMyD88 expression was examined by Western blot analysis with anti-MyD88 antibody. We also examined the expression of FLAG epitope by Western blot analysis with specific antibody. As shown in Fig. 3A, GFP expression was observed in most cardiac cells, including cardiomyocytes, after transfection of Ad5-GFP into the myocardium. Figure 3B shows that expressed dnMyD88 and FLAG were detected in the hearts 3 days and 1 and 2 wk after transfection with Ad5-dnMyD88 but not detected in the hearts transfected with Ad5-GFP. There was no detectable transfected dnMyD88 or FLAG 3 wk after transfection.


Figure 3
View larger version (103K):
[in this window]
[in a new window]
  		Fig. 3. Expression of dnMyD88 in the myocardium. Rat hearts were directly transfected with Ad5-GFP or Ad5-dnMyD88 (1 x 1010 pfu/ml). A: 3 days after transfection of Ad5-GFP, the hearts were harvested, sectioned, and visualized with white light (left) and fluorescent light (right) under microscopy. GFP expression mainly locates in cardiac myocytes. B: 3 days after transfection, the cytoplasmic proteins were isolated from the hearts, and the expression of FLAG and dnMyD88 was examined by Western blot analysis with specific antibodies. The expressed FLAG or dnMyD88 is labeled on the right.

 
Transfection of dnMyD88 attenuates cardiac hypertrophy. To determine whether blocking MyD88-dependent NF-{kappa}B activation could attenuate the development of cardiac hypertrophy in vivo, we transfected Ad5-dnMyD88 (n = 8) or Ad5-GFP (n = 8) into the myocardium immediately followed by aortic banding. Three weeks after aortic banding, the hearts were harvested and HW/BW and heart weight/tibia length (HW/TL) were calculated. As shown in Fig. 4, A and B, aortic banding for 3 wk significantly increased HW/BW by 41.0% (0.44 ± 0.013 vs. 0.31 ± 0.008) and HW/TL by 47.2% (42.7 ± 1.30 vs. 29.0 ± 0.69) compared with sham controls. Transfection of Ad5-dnMyD88 significantly reduced HW/BW by 18.2% (0.36 ± 0.006 vs. 0.44 ± 0.013) and HW/TL by 22.3% (33.2 ± 0.95 vs. 42.7 ± 1.30), respectively, compared with aortic-banded hearts without transfection. Transfection of Ad5-GFP did not significantly alter the aortic banding-increased ratio of HW/BW. The reduced HW/BW by dnMyD88 was due to decreased left ventricular weight, and there were no differences in body weights compared with the untreated group (sham: 317.1 ± 7.36 g; banding: 315.0 ± 3.82 g; GFP: 318.3 ± 5.63 g; dnMyD88: 312.0 ± 4.89 g). Figure 4C shows that the cardiac myocyte area from the left ventricle of aortic-banded hearts was increased by 49.6% compared with sham control. The cell area of hearts from aortic-banded rats transfected with dnMyD88 was increased by 21.4% compared with the dnMyD88-transfected sham control. Thus transfection of dnMyD88 suppressed the aortic banding increase in the myocyte cell size by 56.8%. Transfection of Ad-GFP did not significantly affect the aortic banding increase in cardiac myocyte size (Fig. 4C).


Figure 4
View larger version (60K):
[in this window]
[in a new window]
  		Fig. 4. Transfection of Ad5-dnMyD88 attenuates aortic banding-induced cardiac hypertrophy. Ad5-dnMyD88 or Ad5-GFP (1 x 1010 pfu/ml) was transfected into rat hearts immediately followed by banding the aorta. Three weeks after aortic banding, the hearts were harvested and the ratios of heart weight to body weight (HW/BW) (A) and heart weight to tibia length (HW/TL) (B) were analyzed. There were 8 rats per group. Photographs of representative hearts are shown at the top of A. C: transfection of Ad5-dnMyD88-reduced aortic banding increased cardiac myocyte size. The cardiac myocyte size was examined by FITC-labeled wheat germ agglutinin staining. Left ventricular cardiac myocyte membranes were observed by fluorescence microscopy. Representative heart sections (right) from sham, aortic-banded rats, aortic-banded rats transfected with Ad5-GFP or Ad5-dnMyD88. Left, quantitative analysis of cardiac myocyte size. *P < 0.05 compared with age-matched, sham-operated controls; #P < 0.05 compared with aortic banding group; &P < 0.05 compared with aortic banding + GFP group.

 
Transfection of dnMyD88 inhibits aortic banding-increased NF-{kappa}B activation. To investigate whether blocking MyD88-mediated signaling will decrease NF-{kappa}B activation in the hearts subjected to aortic banding, we transfected Ad5-dnMyD88 into the myocardium immediately followed by banding the aorta (n = 8). Transfection of Ad5-GFP served as control (n = 8). Three weeks after transfection, hearts were harvested and nuclear proteins were isolated for measurement of NF-{kappa}B binding activity by EMSA. As shown in Fig. 5A, aortic banding for 3 wk significantly increased NF-{kappa}B binding activity by 145.4% compared with sham controls. Transfection of Ad5-dnMyD88, however, significantly reduced NF-{kappa}B binding activity by 41.8% compared with the untreated aortic-banded group. Transfection of Ad5-GFP did not affect aortic banding-increased NF-{kappa}B binding activity in the myocardium. The specificity of NF-{kappa}B activity in the hypertrophic hearts was confirmed by the addition of 100-fold excess of unlabeled NF-{kappa}B or activated protein II oligonucleotides into the EMSA reaction. Unlabeled NF-{kappa}B oligonucleotides competed for the binding nuclear proteins prepared from aortic-banded rat hearts (Fig. 5B), whereas the activated protein II oligonucleotides did not. The predominant protein complex of NF-{kappa}B containing P50 and P65 subunits in the hypertrophic hearts was demonstrated by antibody supershift assays. Both antibodies, when added separately or together, shifted the major NF-{kappa}B binding complex.


Figure 5
View larger version (50K):
[in this window]
[in a new window]
  		Fig. 5. Transfection of Ad5-dnMyD88 reduces aortic banding-increased NF-{kappa}B binding activity. A: Ad5-dnMyD88 or Ad5-GFP (1 x 1010 pfu/ml) was transfected into rat hearts immediately followed by banding the aorta. Three weeks after aortic banding was completed, the hearts were harvested and nuclear proteins were isolated for measurement of NF-{kappa}B binding activity by EMSA. There were 8 rats per group. *P < 0.05 compared with age-matched sham-operated controls; #P < 0.05 compared with aortic banding group. Representative EMSA results are shown on the right; NF-{kappa}B binding bands are labeled on the right. B: specificity of NF-{kappa}B binding activity was analyzed by addition of unlabeled oligonucleotides and by an antibody supershift gel assay. NF-{kappa}B banding activity was examined from the heart samples subjected to aortic banding for 3 wk. NF-{kappa}B and the nonspecific binding band (nb) are labeled on the left and the raised bands supershifted by antibodies are indicated to the right. Free probe is not shown.

 
Transfection of dnMyD88 reduces cardiac myocyte apoptosis following pressure overload. Aortic banding-induced cardiac hypertrophy exhibited extensive cardiac myocyte death and increase in fibrosis (Fig. 6, A–C). The TUNEL assay shows that cardiac myocyte apoptosis in aortic-banded hearts was significantly increased by 11.5% compared with sham control (Fig. 6B). Caspase-3 activity in the aortic-banded hearts was also increased as evidenced by immunohistochemistry with specific anti-cleaved caspase-3 antibody (Fig. 6C). Myocardial fibrosis was also increased in the hypertrophic hearts as evidenced by Masson's Trichrome staining (Fig. 6D). To evaluate whether blocking the MyD88-dependent NF-{kappa}B activation pathway could improve morphology of aortic-banded hearts, we transfected Ad5-dnMyD88 into the myocardium immediately followed by aortic banding for 3 wk. We observed that transfection of dominant negative MyD88 significantly improved the morphology of aortic-banded hearts (Fig. 6A). In Ad5-Myd88-transfected hearts, cardiac myocyte apoptosis was only increased 2.7% following aortic banding for 3 wk (Fig. 6B). Thus blocking the MyD88-dependent pathway reduced aortic banding-induced cardiac myocyte apoptosis by 76.2%. Caspase-3 activity was also reduced in the hearts transfected with Ad5-dnMyD88 (Fig. 6C). In addition, transfection of Ad5-dnMyD88 significantly reduced myocardial fibrosis in aortic-banded hearts (Fig. 6D). Transfection of Ad5-GFP had no effect on the improvement of morphology, cardiac myocyte apoptosis, and myocardial fibrosis in aortic-banded hearts (Fig. 6, A–C).


Figure 6
View larger version (63K):
[in this window]
[in a new window]
  		Fig. 6. Transfection of dnMyD88 improves morphology of hypertrophic hearts in vivo. Rat hearts were directly transfected with Ad5-GFP or Ad5-dnMyD88 (1 x 1010 pfu/ml) immediately followed by banding the aorta. After 3 wk of aortic banding with and without transfection, the hearts were harvested, sectioned, and embedded in paraffin. A: heart sections were counterstained with hematoxylin and eosin (n = 4 hearts/group). Representative photomicrographs demonstrating morphology of heart sections from sham (a–c), aortic banding (d–f), and aortic banding with Ad5-GFP (g–i), and aortic banding with Ad5-dnMyD88 (j–l) are shown. Original magnification was x4, x10, and x20, respectively. B: cardiac cell apoptosis was examined by terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay. C: caspase-3 activity was examined by immunohistochemistry with specific anti-cleaved caspase-3 antibody (n = 4/group). Representative photomicrographs demonstrating cardiac cell apoptosis of heart sections from sham (a), aortic banding (b), sham + Ad5-GFP (c), aortic banding + Ad5-GFP (d), sham + Ad5-dnMyD88 (e), and aortic banding + Ad5-dnMyD88 (f) are shown. For TUNEL assay, blue color shows the nucleus of each cell and the dark brown color indicates positive cardiac myocyte apoptosis, which is marked by a red arrow. For immunohistochemistry analysis of caspase-3 activity, brown color indicates positive cells marked by red arrows. Left, quantitative analysis of the apoptotic cells. *P < 0.05 compared with age-matched representative sham control; #P < 0.05 compared with the aortic banding group; &P < 0.05 compared with aortic banding + GFP group. D: myocardial interstitial fibrosis was examined by Masson's trichrome staining (n = 4/group). Representative photomicrographs demonstrating myocardial interstitial fibrosis of heart sections from sham (a and b), aortic banding (c and d), aortic banding with Ad5-GFP (e and f), and aortic banding with Ad5-dnMyD88 (g and h) are shown.

 
Hemodynamic measurements. In vivo cardiac function was measured 3 wk after aortic banding by the Millar pressure-volume conductance system. Figure 7A shows that aortic banding-induced cardiac hypertrophy resulted in significant reduction of cardiac output by 60.0%, ejection fraction by 53.6%, stroke volume by 58.0%, and stroke work by 47.7% compared with sham control. Blockade of MyD88 by transfection of Ad5-dnMyD88, however, significantly improved cardiac function, evidenced by increased cardiac output by 33.3%, ejection fraction by 32.8%, stroke volume by 38.0%, and stroke work by 31.1% when compared with aortic-banded rats. Transfection with Ad5-GFP did not produce any significant changes compared with control animals. Representative pressure-volume loops from each group of animals are also presented (Fig. 7B)


Figure 7
View larger version (30K):
[in this window]
[in a new window]
  		Fig. 7. Transfection of dnMyD88 improves left ventricle (LV) function. Rat hearts were directly transfected with Ad5-GFP or Ad5-dnMyD88 (1 x 1010 pfu/ml) immediately followed by banding the aorta. A: after 3 wk of aortic banding with and without transfection, LV hemodynamic parameters were examined. There were 5 rats in each group. *P < 0.05 compared with age-matched representative sham control; #P < 0.05 compared with the aortic banding group. B: representative pressure-volume loops from each group of animals

 

   DISCUSSION
TOP
 ABSTRACT
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
A significant finding of this study is that blocking the MyD88-mediated NF-{kappa}B activation pathway by transfection of an adenovirus expressing dominant negative MyD88 (Ad5-dnMyD88) into the myocardium significantly reduced cardiac myocyte apoptosis and improved cardiac function following pressure overload. This result suggests that the MyD88-dependent NF-{kappa}B activation pathway contributes to cardiac myocyte apoptosis in pressure overload-induced cardiac hypertrophy in vivo.

MyD88 is an important immediate downstream adaptor molecule that interacts directly with the TIR domain of TLRs on the cell plasma membrane (23). After recognition of ligands by TLRs, MyD88 recruits IRAK, which stimulates TRAF6, leading to activation of IKKs, which stimulates I{kappa}B{alpha} phosphorylation and degradation, resulting in NF-{kappa}B translocation to the nucleus, binding to target DNA sequences, and stimulation of gene expression. A role of NF-{kappa}B activation in the hypertrophic response of cultured cardiomyocytes has been documented. For example, activation of NF-{kappa}B is required for hypertrophic growth of cultured neonatal cardiomyocytes (27) and for myotrophin-induced cardiac hypertrophy in vitro (12). A20, a feedback inhibitor of NF-{kappa}B activation (8), attenuated the hypertrophic response of cardiomyocytes in vitro through the inhibition of NF-{kappa}B signaling (8). We have previously demonstrated that NF-{kappa}B activation is required for the development of cardiac hypertrophy in vivo and inhibiting NF-{kappa}B activation attenuated aortic banding-induced cardiac hypertrophy (21). We have also observed that TLR4-deficient mice are resistant to aortic banding-induced cardiac hypertrophy (13), suggesting that TLR4 could be an important contributor to cardiac hypertrophy in vivo. Collectively, our previous observations suggest that TLR4-mediated signaling leading to NF-{kappa}B activation could be a novel pathway contributing to the development of cardiac hypertrophy in vivo (13, 21). Because MyD88 is an adaptor protein for TLR-mediated signaling leading to NF-{kappa}B activation, we evaluated the effect of blocking the MyD88-mediated signaling pathway on the cardiac hypertrophy in vivo. We constructed an adenovirus expressing dominant negative MyD88 (Ad5-MyD88) and transfected it into the myocardium immediately followed by banding the aorta for 3 wk. We have observed that transfection of this defective MyD88 into the myocardium significantly reduced aortic banding-induced cardiac hypertrophy, whereas transfection of Ad5-GFP did not. Transfection of Ad5-dnMyD88 into the myocardium significantly reduced aortic banding-increased NF-{kappa}B binding activity. In addition, we observed in our in vitro study that transfection of Ad5-dnMyD88 into rat cardiomyoblasts significantly inhibited NF-{kappa}B activation stimulated by LPS. Our observation is consistent with other reports showing that overexpression of dominant negative deletion mutants of MyD88 inhibited IL-1-induced activation of NF-{kappa}B (6, 15, 24, 30) and prevented TLR4-mediated NF-{kappa}B activation by LPS (10). Macrophages isolated from MyD88-deficient mice are completely defective in the production of an inflammatory response to the stimulation by bacterial components, suggesting that MyD88 plays a significant role in TLR-mediated signaling pathways (7, 10).

The role of cardiomyocyte apoptosis in the transition of the hypertrophic hearts to heart failure has been documented (9, 25, 29). However, the mechanisms by which cardiac myocyte apoptosis occurs during the development of cardiac hypertrophy are still unclear. Recent evidence suggests that MyD88 plays a role in mediating apoptosis (3, 9). Overexpression of MyD88 significantly induced a delayed cytotoxic effect in cultured cells (6). MyD88 consists of an NH2-terminal death domain and a COOH-terminal TIR domain. Both domains are separated by a short linker sequence. In the death domain of MyD88, there is a motif of ~90 amino acids originally identified as apoptosis-promoting proteins. Interestingly, we have observed that there is abundant loss of cardiac myocytes and cardiac myocyte apoptosis as well as fibrosis in the hypertrophic hearts induced by aortic banding for 3 wk. To evaluate whether MyD88 contributes to the myocyte apoptosis during the development of cardiac hypertrophy, we transfected Ad5-dnMyD88 into the myocardium immediately followed by aortic banding for 3 wk. We have observed that transfection of dnMyD88 significantly reduced cardiac myocyte apoptosis and fibrosis with concomitant improvement of cardiac function, suggesting that the death domain of MyD88-mediated signaling could be involved in stimulating the expression of pro-cell death genes during the development of cardiac hypertrophy.

Our previous studies (13, 21) have suggested that the TLR4-mediated MyD88-dependent NF-{kappa}B activation pathway contributes to the development of cardiac hypertrophy in vivo. Our current observation is supported by recent reports showing that activation of the intermediates of TLR4-mediated MyD88-dependent NF-{kappa}B signaling is involved in the hypertrophic response (11, 26, 33). For example, TLR4 expression was significantly increased in the failing human heart (5, 11, 28). Transforming growth factor-beta [TGF-beta-activated kinase-1 (TAK-1)] activity, a key kinase in the TLR-mediated NF-{kappa}B activation pathway, was significantly increased in the heart following aortic banding (33). Cardiac specific expression of constitutively active TAK-1 in transgenic mice resulted in cardiac hypertrophy (33). IKKbeta is an important kinase for phosphorylation and degradation of I{kappa}B{alpha}, resulting in activation of NF-{kappa}B. Inhibiting IKKbeta activity by transfecting the IKKbeta dominant-negative mutant into cultured cardiomyocytes prevented the hypertrophic response of cardiomyocytes through inhibition of NF-{kappa}B activation (27). Collectively, these data suggest that the TLR4-mediated, MyD88-dependent NF-{kappa}B activation pathway plays a role in the development of cardiac hypertrophy.

In summary, we have observed that blockade of MyD88 by transfection of Ad5-dnMyD88 into the myocardium significantly attenuates aortic banding-induced cardiac hypertrophy in vivo, reduces cardiac myocyte apoptosis, and improves cardiac function following pressure overload. Our results suggest that MyD88 is an important participant in aortic banding-induced hypertrophy in vivo.


   ACKNOWLEDGMENTS
 
This work was supported in part by American Heart Association (AHA) Grants AHA-0051480B and AHA-0255038B and National Institutes of Health (NIH) Grants RO1 HL-071837 to C. Li. This work was also supported in part by NIH Grants GM-53552, AI-45829, and AT-00501 to D. L. Wiliams; by the East Tennessee State University Research Development Committee grant to T. Ha; NIH Grants HL-72138 and AHA-0255009B to R. L. Kao; and National Gongguan Project of China 2001BA710B to X. Gao.


   FOOTNOTES
 

Address for reprint requests and other correspondence: C. Li, Dept. of Surgery, East Tennessee State Univ., Campus Box 70575, Johnson City, TN 37614-0575 (e-mail: Li{at}ETSU.EDU)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


   REFERENCES
TOP
 ABSTRACT
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Aderem A and Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature 406: 782–787, 2000.[CrossRef][Medline]
  2. Baeuerle PA and Baltimore D. NF–{kappa}B: ten years after. Cell 87: 13–20, 1996.[CrossRef][Web of Science][Medline]
  3. Bannerman DD, Tupper JC, Kelly JD, Winn RK, and Harlan JM. The Fas-associated death domain protein suppresses activation of NF–{kappa}B by LPS and IL-1beta. J Clin Invest 109: 419–425, 2002.[CrossRef][Web of Science][Medline]
  4. Beyaert R, Heyninck K, and Van Huffel S. A20 and A20-binding proteins as cellular inhibitors of nuclear factor-kappa B-dependent gene expression and apoptosis. Biochem Pharmacol 60: 1143–1151, 2000.[CrossRef][Web of Science][Medline]
  5. Birks EJ, Felkin LE, Banner NR, Khaghani A, Barton PJ, and Yacoub MH. Increased toll-like receptor 4 in the myocardium of patients requiring left ventricular assist devices. J Heart Lung Transplant 23: 228–235, 2004.[CrossRef][Web of Science][Medline]
  6. Burns K, Martinon F, Esslinger C, Pahl H, Schneider P, Bodmer JL, Di Marco F, French L, and Tschopp J. MyD88, an adapter protein involved in interleukin-1 signaling. J Biol Chem 273: 12203–12209, 1998.[Abstract/Free Full Text]
  7. Chanzy H, Dube M, Marchessault RH, and Revol JF. Single crystals and oriented crystallization of ivory nut mannan. Biopolymers 18: 887–898, 1979.[CrossRef]
  8. Cook SA, Novikov MS, Ahn Y, Matsui T, and Rosenzweig A. A20 is dynamically regulated in the heart and inhibits the hypertrophic response. Circulation 108: 664–667, 2003.[Abstract/Free Full Text]
  9. Dupraz P, Cottet S, Hamburger F, Dolci W, Felley-Bosco E, and Thorens B. Dominant negative MyD88 proteins inhibit interleukin-1beta/interferon-{gamma}-mediated induction of nuclear factor {kappa}B-dependent nitrite production and apoptosis in beta cells. J Biol Chem 275: 37672–37678, 2000.[Abstract/Free Full Text]
  10. Fitzgerald KA, Palsson-McDermott EM, Bowie AG, Jefferies CA, Mansell AS, Brady G, Brint E, Dunne A, Gray P, Harte MT, McMurray D, Smith DE, Sims JE, Bird TA, and O'Neill LA. Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction. Nature 413: 78–83, 2001.[CrossRef][Medline]
  11. Frantz S, Kobzik L, Kim YD, Fukazawa R, Medshitov R, Lee RT, and Kelly RA. Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest 104: 271–280, 1999.[Web of Science][Medline]
  12. Gupta S, Purcell NH, Lin A, and Sen S. Activation of nuclear factor-kappaB is necessary for myotrophin-induced cardiac hypertrophy. J Cell Biol 159: 1019–1028, 2002.[Abstract/Free Full Text]
  13. Ha T, Li Y, Hua F, Ma J, Gao X, Kelley J, Zhao A, Haddad GE, Williams DL, Browder IW, Kao RL, and Li C. Reduced cardiac hypertrophy in toll-like receptor 4-deficient mice following pressure overload. Cardiovasc Res 68: 224–234, 2005.[Abstract/Free Full Text]
  14. Higuchi Y, Otsu K, Nishida K, Hirotani S, Nakayama H, Yamaguchi O, Matsumura Y, Ueno H, Tada M, and Hori M. Involvement of reactive oxygen species-mediated NF–kappa B activation in TNF-alpha-induced cardiomyocyte hypertrophy. J Mol Cell Cardiol 34: 233–240, 2002.[CrossRef][Web of Science][Medline]
  15. Janssens S, Burns K, Vercammen E, Tschopp J, and Beyaert R. MyD88s, a splice variant of MyD88, differentially modulates NF–{kappa}B and AP-1-dependent gene expression. FEBS Lett 548: 103–107, 2003.[CrossRef][Web of Science][Medline]
  16. Kao RL, Chin TK, Ganote CE, Hossler FE, Li C, and Browder W. Satellite cell transplantation to repair injured myocardium. Card Vasc Regen 1: 31–42, 2000.
  17. Li C, Browder W, and Kao RL. Early activation of transcription factor NF-{kappa}B during ischemia in perfused rat heart. Am J Physiol Heart Circ Physiol 276: H543–H552, 1999.[Abstract/Free Full Text]
  18. Li C, Ha T, Kelley J, Gao X, Qiu Y, Kao RL, Browder W, and Williams DL. Modulating Toll-like receptor mediated signaling by (1->3)-beta-D-glucan rapidly induces cardioprotection. Cardiovasc Res 61: 538–547, 2003.[CrossRef][Web of Science]
  19. Li C, Ha T, Liu L, Browder W, and Kao RL. Adenosine prevents activation of transcription factor NF–kappa B and enhances activator protein-1 binding activity in ischemic rat heart. Surgery 127: 161–169, 2000.[CrossRef][Web of Science][Medline]
  20. Li C, Kao RL, Ha T, Kelley J, Browder IW, and Williams DL. Early Activation of IKKbeta during in vivo myocardial ischemia. Am J Physiol Heart Circ Physiol 280: H1264–H1271, 2001.[Abstract/Free Full Text]
  21. Li Y, Ha T, Gao X, Kelley J, Williams DL, Browder IW, Kao RL, and Li C. NK-{kappa}B activation is required for the development of cardiac hypertrophy in vivo. Am J Physiol Heart Circ Physiol 287: H1712–H1720, 2004.[Abstract/Free Full Text]
  22. Li YH, Ha TZ, Chen Q, and Li CF. Role of MyD88-dependent nuclear factor-kappaB signaling pathway in the development of cardiac hypertrophy in vivo. Zonghua Yi Xue Za Zhi 85: 267–272, 2005.
  23. Medzhitov R, Preston-Hurlburt P, and Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388: 394–397, 1997.[CrossRef][Medline]
  24. Medzhitov R, Preston-Hurlburt P, Kopp E, Stadlen A, Chen C, Ghosh S, and Janeway CA. MyD88 is an adaptor protein in the hToll/Il-1 receptor family signaling pathways. Mol Cell 2: 253–258, 1998.[CrossRef][Web of Science][Medline]
  25. Nadal-Ginard B, Kajstura J, Leri A, and Anversa P. Myocyte death, growth, and regeneration in cardiac hypertrophy and failure. Circ Res 92: 139–150, 2003.[Abstract/Free Full Text]
  26. Purcell NH and Molkentin JD. Is nuclear factor {kappa}B an attractive therapeutic target for treating cardiac hypertrophy? Circulation 108: 638–640, 2003.[Free Full Text]
  27. Purcell NH, Tang G, Yu C, Mercurio F, DiDonato JA, and Lin A. Activation of NF–{kappa}B is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes. PNAS 98: 6668–6673, 2001.[Abstract/Free Full Text]
  28. Satoh M, Nakamura M, Akatsu T, Shimoda Y, Segawa I, and Hiramori K. Toll-like receptor 4 is expressed with enteroviral replication in myocardium from patients with dilated cardiomyopathy. Lab Invest 84: 173–181, 2004.[CrossRef][Web of Science][Medline]
  29. Van Empel VPM and De Windt LJ. Myocyte hypertrophy and apoptosis: a balancing act. Cardiovasc Res 63: 487–499, 2004.[Abstract/Free Full Text]
  30. Wesche H, Henzel WJ, Shillinglaw W, Li S, and Cao Z. MyD88: an adapter that recruits IRAK to the IL-1 receptor complex. Immunity 7: 837–847, 1997.[CrossRef][Web of Science][Medline]
  31. Williams DL, Li C, Ha T, Ozment-Skelton T, Kalbfleisch JH, Preiszner J, Brooks L, Breuel K, and Schweitzer JB. Modulation of the phosphoinositide 3-kinase pathway alters innate resistance to polymicrobial sepsis. J Immunol 172: 449–456, 2004.[Abstract/Free Full Text]
  32. Yamamoto K, Ohki R, Lee RT, Ikeda U, and Shimada K. Peroxisome proliferator-activated receptor {gamma} activators inhibit cardiac hypertrophy in cardiac myocytes. Circulation 104: 1670–1675, 2001.[Abstract/Free Full Text]
  33. Zhang D, Gaussin V, Taffet GE, Belaguli NS, Yamada M, Schwartz RJ, Michael LH, Overbeek PA, and Schneider MD. TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice. Nat Med 6: 556–563, 2000.[CrossRef][Web of Science][Medline]
  34. Zhang G and Ghosh S. Toll-like receptor-mediated NF–{kappa}B activation: a phylogenetically conserved paradigm in innate immunity. J Clin Invest 107: 13–19, 2001.[Web of Science][Medline]



This article has been cited by other articles:


Home page
 J. Thorac. Cardiovasc. Surg.Home page
Y.-H. Choi, D. B. Cowan, A. M. Moran, S. D. Colan, C. Stamm, K. Takeuchi, I. Friehs, P. J. del Nido, and F. X. McGowan Jr.
Myocyte apoptosis occurs early during the development of pressure-overload hypertrophy in infant myocardium.
J. Thorac. Cardiovasc. Surg., June 1, 2009; 137(6): 1356 - 1362.e3.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
T. Ha, F. Hua, X. Liu, J. Ma, J. R. McMullen, T. Shioi, S. Izumo, J. Kelley, X. Gao, W. Browder, et al.
Lipopolysaccharide-induced myocardial protection against ischaemia/reperfusion injury is mediated through a PI3K/Akt-dependent mechanism
Cardiovasc Res, June 1, 2008; 78(3): 546 - 553.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
T. Ha, F. Hua, D. Grant, Y. Xia, J. Ma, X. Gao, J. Kelley, D. L. Williams, J. Kalbfleisch, I. W. Browder, et al.
Glucan phosphate attenuates cardiac dysfunction and inhibits cardiac MIF expression and apoptosis in septic mice
Am J Physiol Heart Circ Physiol, October 1, 2006; 291(4): H1910 - H1918.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
290/3/H985    most recent
00720.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (10)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ha, T.
Right arrow Articles by Li, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ha, T.
Right arrow Articles by Li, C.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2006 by the American Physiological Society.